High-dose fluconazole therapy in patients with severe fungal infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 3, 1999, Pages 165-174

  Voss, A ^a   De Pauw, B E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ALOPECIA; ANOREXIA; ARTHRALGIA; CANDIDA; DIARRHEA; DISEASE SEVERITY; DRUG MEGADOSE; FATIGUE; GASTRITIS; HEADACHE; HUMAN; MALAISE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; PRIORITY JOURNAL; REVIEW; VERTIGO; VOMITING;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

EID: 0032744406     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050252     Document Type: Review

References (72)

1. 1. Beck-Sague CM, Jarvis WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. Journal of Infectious Diseases (1993) 167:1247-1251
2. 2. Jarvis WR, Martone WJ: Predominant pathogens in hospital infections. Journal of Antimicrobial Chemotherapy (1992) 29 Supplement A: 19-24
3. 3. Pfaller MA, Wenzel RP: Impact of the changing epidemiology of fungal infections in the 1990s. European Journal of Clinical Microbiology & Infectious Diseases (1992) 11:287-291
4. 4. Schaberg DR, Culver DH, Gaynes RP: Major trends in the microbial etiology of nosocomial infection. American Journal of Medicine (1991), 91, Supplement 3B: 72-75
5. 5. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Archives of Internal Medicine (1988) 148:2642-2645
6. 6. Brooks RG: Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Archives of Internal Medicine (1989) 149:2226-2228
7. 7. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC: Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clinical Infectious Diseases (1992) 15:414-421
8. 8. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, Pizzo PA, Walsh TJ: Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clinical Infectious Diseases (1992) 148:875-883
9. 9. Solomkin JS: Pathogenesis and management of Candida infection syndromes in non-neutropenic patients. New Horizons (1993) 1:202-213
10. 10. DeMuri GP, Hostetter MK: Resistance to antifungal agents. Pediatric Clinics of North America (1995) 42:665-685
11. 11. Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN: Investigation of the sequence of colonization and candidemia in nonneutropenic patients. Journal of Clinical Microbiology (1994) 32:975-980
12. 12. Como JA, Dismukes WE: Oral azole drugs as systemic antifungal therapy. New England Journal of Medicine (1994) 330:263-272
13. 13. Kullberg BJ, Voss A: The changing pattern of Candida infections: different species and increased resistance. Nederlands Tijdschrift voor Geneeskunde (1996) 140:148-151
14. 14. Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clinical Infectious Diseases (1995) 20:115-125
15. 15. Wenzel RP: Nosocomial candidemia: Risk factors and attributable mortality. Clinical Infectious Diseases (1995) 20:1531-1534
16. 16. Komshian SV, Uwaydah AK, Sobel JD, Crane LR: Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Reviews in Infectious Diseases (1989) 11:379-390
17. 17. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrobial Agents and Chemotherapy (1995) 39:1-8
18. 18. Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine Chalberg J, Pfaller MA: Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clinical Infectious Diseases (1994) 18:240-242
19. 19. Odds FC: Resistance of yeast to azole-derivative antifungals. Journal of Antimicrobial Chemotherapy (1993) 31:463-471
20. 20. Ng TTC, Denning D: Fluconazole resistance in Candida in patients with AIDS - a therapeutic approach. Journal of Infection (1993) 26:117-125
21. 21. Millon L, Manteaux A, Reboux C, Drobacheff C, Monod M, Barale T: Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. Journal of Clinical Microbiology (1994) 32:1115-1118
22. 22. Fan Havard P, Capano C, Smith SM, Mangia A, Eng RH: Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrobial Agents and Chemotherapy (1991) 35:2302-2305
23. 23. Barchiesi F, Morbiducci V, Ancarani F, Scalise G: Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. European Journal of Epidemiology (1993) 9:455-456
24. 24. Kunova A, Trupl J, Dluholucky S, Galova G, Krcmery V Jr: Use of fluconazole is not associated with a higher incidence of Candida krusei and other non-albicans Candida species. Clinical Infectious Diseases (1995) 21:226-227
25. 25. Kunova A, Trupl J, Spanik S, Drgona L, Sufliarsky J, Lacka J, Studena V, Hlavacova E, Studena M, Kukuckova E: Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole. Chemotherapy (1995) 41:39-44
26. 26. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Hadduck RK, Shea T, Stiff P, Friedman DJ, Powderley WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Nangan KGF, Silver SM, Weisdorf D, Ho WG, Gilver G, Buell D: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine (1992) 326:845-851
27. 27. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, Ricci P, Carotenuto M, Liso V, Nosari AM, Barbui T, Fasola G, Mandelli F: The GIMEMA Infection Program: preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Annals of Internal Medicine (1994) 120:913-918
28. 28. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schachter B: Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission induction therapy for acute myeloid leukemia in adults. Journal of Clinical Oncology (1997) 15:2254-2261
29. 29. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD: Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy (1995) 39:40-44
30. 30. Galgiani J, Reiser NJ, Brass C, Espinel Ingroff A, Gordon MA, Kerkering TM: Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrobial Agents and Chemotherapy (1987) 31:1343-1347
31. 31. Rex JH, Pfaller MA, Galgiani JN: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clinical Infectious Diseases (1997) 24:235-247
32. 32. Galgiani JN: Susceptibility testing of fungi: current status of the standardization process. Antimicrobial Agents and Chemotherapy (1993) 37:2517-2521
33. 33. Ghannoum MA: Is antifungal susceptibility testing useful in guiding fluconazole therapy? Clinical Infectious Diseases (1996), 22, Supplement 2:161-165
34. 34. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-P. NCCLS, Villanova, PA (1992)
35. 35. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-A. NCCLS, Villanova, PA (1977)
36. 36. Barry AL, Brown SD: Fluconazole disk diffusion procedure for determining susceptibility of Candida species. Journal of Clinical Microbiology (1996) 34:2154-2157
37. 37. Colombo AL, Barchiesi F, McGough DA: Evaluation of the E-test system versus a microtitre broth method for antifungal susceptibility testing of yeasts against fluconazole and itraconazole. Journal of Antimicrobial Chemotherapy (1995) 36:93-100
38. 38. McIntyre KA, Galgiani JN: In vitro susceptibility of yeasts to a new antifungal triazole, SCH 39304:effects of test conditions and relation to in vivo efficacy. Antimicrobial Agents and Chemotherapy (1989) 33:1095-1100
39. 39. Powderly WG, Kobayashi GS, Herzig GP: Amphotericin B-resistant yeast infection in severely immunocompromised patients. American Journal of Medicine (1988) 84:826-832
40. 40. Calhoun DL, Washkin H, White MP: Treatment of systemic sporotrichosis with ketoconazole. Reviews of Infectious Diseases (1991) 13:47-51
41. 41. Rogers TE, Galgiani JN: Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrobial Agents and Chemotherapy (1986) 30:418-422
42. 42. Ghannoum MA, Rex JH, Galgiani JN: Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. Journal of Clinical Microbiology (1996) 34:489-495
43. 43. Edwards JE, Bodey GP, Bowden RA, Buchner T, De Pauw BE: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clinical Infectious Diseases (1997) 25:43-59
44. 44. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC: Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clinical Infectious Diseases (1992) 15:414-421
45. 45. Bille J, Glauser MP: Evaluation of the susceptibility of pathogenic Candida species to fluconazole. European Journal of Clinical Microbiology & Infectious Diseases (1997) 16:924-928
46. 46. Jarvis WR, Martone WJ: Predominant pathogens in hospital infections. Journal of Antimicrobial Chemotherapy (1992), 29, Supplement A: 19-24
47. 47. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M: The prevalence of nosocomial infection in ICUs in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Journal of the American Medical Association (1995) 274:639-644
48. 48. Brooks RG: Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Archives of Internal Medicine (1989) 149:2226-2228
49. 49. Menezes AV, Sigesmund DA, Demajo WA, Devenyi RG: Mortality of hospitalized patients with Candida endophthalmitis. Archives of Internal Medicine (1994) 154:2093-2097
50. 50. Voss A, le Noble JL, Verduyn-Lunel FM, Foudraine NA, Meis JF: Candidemia in intensive care unit patients: risk factors for mortality. Infection (1997) 25:8-11
51. 51. Voss A, Kluytmans JS, Koeleman HG, Spanjaard L, Vandenbroucke-Grauls CM, Verbrugh HA, Vos MC, Weersink AJ, Hoogkamp-Korstanje JA, Meis JF: Occurrence of yeast bloodstream infection in Dutch university hospitals between 1987 and 1995. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:909-912
52. 52. Verduyn Lunel FM, Voss A, Neeleman C, Meis JF: Candidemia due to Candida krusei in a non-neutropenic intensive care patient. Nederlands Tijdschrift voor Medische Microbiologie (1996) 4:28-29
53. 53. Duswald KH, Penk A, Pittrow L: High dose therapy with fluconazole (F) ≥ 800 mg/day. Mycoses (1997) 40:267-277
54. 54. Grant SM, Clisshold SP: Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses, Drugs (1990) 39:877-916
55. 55. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A: Treatment of Candida albicans fungaemia with fluconazole. Journal of Infection (1993) 26:133-146
56. 56. de Pauw BE, Raemaekers JMM, Donnelly JP, Kullberg B-J, Meis JFGM: An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of Hematology (1995) 70:83-87
57. 57. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II, Gilbreath J, Bodey GP: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. American Journal of Medicine (1996) 101:170-176
58. 58. Anaissie EJ, Darouiche RO, Abi-Said D, Mera J, Gentry LO, Williams T, Kontoyiannis DP, Karl CL, Bodey GP: Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and a review of the literature. Clinical Infectious Diseases (1996) 23:964-972
59. 59. Kaufman CA, Bradley SF, Ross SC, Weber DR: Hepatosplenic candidiasis: successful treatment with fluconazole. American Journal of Medicine (1991) 91:137-141
60. 60. Wheat LJ: Histoplasmosis. Infectious Disease Clinics of North America (1988) 2:841-860
61. 61. Knoper SR, Galgiani JN: Coccidioidomycosis. Infectious Disease Clinics of North America (1988) 2:861-876
62. 62. Diaz M, Negroni R, Montero-Gei F, Castro LG, Sampaio SA, Borelli D, Restrepo A, Franco L, Bran JL, Arathoon EG: A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clinical Infectious Diseases (1992) 14, Supplement 1:68-76
63. 63. Stevens DA, Diaz M, Negroni F, Montero-Gei F, Castro LG, Sampaio SA, Borelli D, Restrepo A, Franco L, Bran JL, Arathoon EG: Safety evaluation of chronic fluconazole therapy. Chemotherapy (1997) 43:371-377
64. 64. Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA, Bosso J, Bodey GP: Safety, plasma concentrations, and efficacy of fluconazole in invasive mould infections. Journal of Infectious Diseases (1995) 172:599-602
65. 65. Larsen RA, Leal MAE, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis. Antimicrobial Agents and Chemotherapy (1990) 113:183-187
66. 66. Bozzette SA, Larsen RA, Chiu M, Jacobson J, Rothman P, Robinson P, Gilbert G, McCutchan JA, Tilles J: A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. New England Journal of Medicine (1991) 324:580-584
67. 67. Kovacs JA, Kovacs AA, Polis M, Wright WC, Gill VJ, Tuazon CU, Gelemann EP, Lane HC, Longfield R, Overturf G: Cryptococcosis in the acquired immunodeficiency syndrome. Annals of Internal Medicine (1985) 103:533-538
68. 68. Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG: Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. Journal of Infectious Diseases (1987) 157:178-180
69. 69. Jones PD, Marriott DJE, Speed BR: Efficacy of fluconazole in cryptococcal meningitis. Diagnostic Microbiology and Infectious Disease (1989) 12, Supplement 4:235-238
70. 70. Berry AJ, Rinaldi MG, Graybill JR: Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrobial Agents and Chemotherapy (1992) 36:90-92
71. 71. Menichetti F, Fiorio M, Tosti A, Gatti G, Bruna Pasticci M, Miletich F, Marroni M, Bassetti D, Pauluzzi S: High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases (1996) 22:838-840
72. 72. Haubrich RH, Haghighat D, Bozzette SA, Tilles J, McCutchan JA: High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group. Journal of Infectious Diseases (1994) 170:238-242